Pentoxifylline as Add-On Treatment to Donepezil in Copper Sulphate-Induced Alzheimer’s Disease-Like Neurodegeneration in Rats
Open Access
- 12 October 2023
- journal article
- research article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 41 (6) , 546-558
Abstract
Alzheimer’s disease (AD), the most common neurodegenerative disorder, is characterized by behavioral, cognitive, and progressive memory impairments. Extensive neuronal loss, extracellular accumulation of insoluble senile amyloid-β (Aβ) plaques, and intracellular neurofibrillary tangles (NFTs) are the major pathological features. The present study aimed to investigate the therapeutic effect of donepezil (DON) and pentoxifylline (PTX) in combination to combat the neurodegenerative disorders (experimental AD) induced by CuSO4intake in experimental rats. Thirty adult male Wistar rats (140–160 g) were used in this study. AD was first induced in rats by CuSO4supplement to drinking water (10 mg/L) for 14 weeks. The AD group received no further treatment. Oral treatment with DON (10 mg/kg/day), PTX (100 mg/kg/day), or DON + PTX for the other three groups was started from the 10th week of CuSO4intake for 4 weeks. Cortex markers like acetylcholine (ACh), acetylcholinesterase (AChE), total antioxidant capacity (TAC), and malondialdehyde (MDA) and hippocampus markers like β-amyloid precursor protein cleaving enzyme 1 (BACE1), phosphorylated Tau (p-tau), Clusterin (CLU), tumor necrosis factor-α (TNF-α), caspase-9 (CAS-9), Bax, and Bcl-2 were measured. The histopathology studies were done by using hematoxylin and eosin and Congo red stains as well as immunohistochemistry for neurofilament. CuSO4induced adverse histological and biochemical changes. The histological injury in the hippocampus was inhibited following the administration of the DON and PTX. The brain tissue levels of AChE, MDA, BACE1, p-tau, CLU, CAS-9, Bax, and TNF-α were significantly increased, while brain tissue levels of ACh, TAC, and Bcl-2 were significantly decreased in CuSO4-treated rats as compared with the untreated control group. The effects induced by either DON or PTX on most studied parameters were comparable. Combined treatment of DON and PTX induced remarkable results compared with their individual use. However, more clinical and preclinical studies are still required to further confirm and prove the long-term efficacy of such combination.Keywords
Funding Information
- Zagazig University
This publication has 66 references indexed in Scilit:
- Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearanceProceedings of the National Academy of Sciences, 2013
- Evaluation of the effect of pentoxifylline on sleep-deprivation induced memory impairmentHippocampus, 2013
- Current and Emerging Drug Treatment Options for Alzheimerʼs DiseaseDrugs, 2011
- Neuropathological Alterations in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Pentoxifylline Promotes Recovery of Erectile Function in a Rat Model of Postprostatectomy Erectile DysfunctionEuropean Urology, 2011
- Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's diseaseNature Neuroscience, 2010
- Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficitsMolecular and Cellular Neuroscience, 2010
- Caspase activation precedes and leads to tanglesNature, 2010
- Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of ADJournal of Neurochemistry, 2009
- Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stainNature Protocols, 2006